ArticleOncology letters2019
Expression and correlation of miR-124 and miR-126 in breast cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.MedComm · 2026Review
- Hypoxia Signaling and Non-Coding RNAs: Regulatory Networks and Therapeutic Implications in Breast Cancer.Current issues in molecular biology · 2026Review
- Exosomal transfer of miR-124 from engineered NK-92 cells inhibits breast cancer cell migration and induces apoptosis.Medical oncology (Northwood, London, England) · 2025Article
- miRNAs Associated with Axillary Lymph Node Metastasis in Breast Cancer: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2025Article
- Mechanisms of apoptosis-related non-coding RNAs in ovarian cancer: a narrative review.Apoptosis : an international journal on programmed cell death · 2025Review
- Expression profile of microRNAs in bovine lymphocytes infected with Theileria annulata and treated with buparvaquone.Parasitology research · 2024Article
- Non-coding RNAs as therapeutic targets in cancer and its clinical application.Journal of pharmaceutical analysis · 2024Review
- MicroRNA-126 (MiR-126): key roles in related diseases.Journal of physiology and biochemistry · 2024Review
- Aged breast matrix bound vesicles promote breast cancer invasiveness.Biomaterials · 2024Article
- Epigenetic modifications: Key players in cancer heterogeneity and drug resistance.Translational oncology · 2024Article
- Differential Expression of Serum Exosomal miRNAs in Breast Cancer Patients and Healthy Controls.Advanced pharmaceutical bulletin · 2022Article
- miRNA therapeutics in precision oncology: a natural premium to nurture.Exploration of targeted anti-tumor therapy · 2022Review
- Non-coding RNA in cancer.Essays in biochemistry · 2021Review
- METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.Cancer gene therapy · 2021Article
- Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of micro ribonucleic acid (miR)-124 and miR-126 in different stages of breast cancer (BC) and their correlation were investigated to analyze the role of miR-124 and miR-126 in the occurrence and development of BC. BC tissues of 83 BC patients treated in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from March 2016 to January 2018 were selected as the research group, while the corresponding para-carcinoma normal tissues were selected as the control group. The relative expression levels of miR-124 and miR-126 in both groups were detected via reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and the miR-124 and miR-126 expression asociated with clinicopathological parameters of patients and the correlation between miR-124 and miR-126 was analyzed. The relative expression levels of miR-124 and miR-126 in the research group were significantly lower than those in the control group (P<0.001). miR-124 and miR-126 in the research group were associated with clinicopathological parameters (clinical stage, degree of pathological differentiation and lymph node metastasis) of patients (P<0.001). According to Pearsons correlation analysis, there was a positive correlation between the relative expression levels of miR-124 and miR-126 in cancer tissues (r=0.497, P<0.001). The expression levels of miR-124 and miR-126 were downregulated in BC tissues, which were associated with clinicopathological parameters (clinical stage, degree of pathological differentiation and lymph node metastasis). There was a positive correlation between the expression levels of miR-124 and miR-126 in BC tissues. Thus, miR-124 and miR-126 may be involved in the occurrence, development, invasion and metastasis of BC, and both can be used as targeted biological indexes for treatment of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.